newsfilter
← Latest News
GlobeNewswire·

Albireo Reports Q4 and Year-End 2021 Financial Results and Business Update

Bylvay™ (odevixibat) launched in the U.S. and Europe, 2021 product revenue, net $7 million NICE endorses clinical and economic benefits of Bylvay Phase 3 study in Alagille syndrome on track for readout in 2022 Reports $248.1 million of cash and ca